Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 2.65
LXRX's Cash to Debt is ranked lower than
69% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. LXRX: 2.65 )
Ranked among companies with meaningful Cash to Debt only.
LXRX' s 10-Year Cash to Debt Range
Min: 1.31  Med: 5.71 Max: No Debt
Current: 2.65
Equity to Asset 0.56
LXRX's Equity to Asset is ranked lower than
64% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. LXRX: 0.56 )
Ranked among companies with meaningful Equity to Asset only.
LXRX' s 10-Year Equity to Asset Range
Min: 0.33  Med: 0.65 Max: 0.96
Current: 0.56
0.33
0.96
F-Score: 3
Z-Score: 0.45
M-Score: 3.51
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -403.00
LXRX's Operating margin (%) is ranked lower than
69% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -71.14 vs. LXRX: -403.00 )
Ranked among companies with meaningful Operating margin (%) only.
LXRX' s 10-Year Operating margin (%) Range
Min: -9955.46  Med: -258.85 Max: -47.73
Current: -403
-9955.46
-47.73
Net-margin (%) -413.73
LXRX's Net-margin (%) is ranked lower than
70% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -67.10 vs. LXRX: -413.73 )
Ranked among companies with meaningful Net-margin (%) only.
LXRX' s 10-Year Net-margin (%) Range
Min: -10120.39  Med: -208.79 Max: -47.98
Current: -413.73
-10120.39
-47.98
ROE (%) -51.46
LXRX's ROE (%) is ranked lower than
63% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. LXRX: -51.46 )
Ranked among companies with meaningful ROE (%) only.
LXRX' s 10-Year ROE (%) Range
Min: -63.41  Med: -38.20 Max: -16.51
Current: -51.46
-63.41
-16.51
ROA (%) -28.56
LXRX's ROA (%) is ranked lower than
51% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. LXRX: -28.56 )
Ranked among companies with meaningful ROA (%) only.
LXRX' s 10-Year ROA (%) Range
Min: -32.59  Med: -26.56 Max: -15.27
Current: -28.56
-32.59
-15.27
ROC (Joel Greenblatt) (%) -762.12
LXRX's ROC (Joel Greenblatt) (%) is ranked lower than
57% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. LXRX: -762.12 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
LXRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -490.12  Med: -152.85 Max: 70.58
Current: -762.12
-490.12
70.58
Revenue Growth (3Y)(%) 95.70
LXRX's Revenue Growth (3Y)(%) is ranked higher than
97% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. LXRX: 95.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
LXRX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -71.1  Med: -19.80 Max: 95.7
Current: 95.7
-71.1
95.7
EBITDA Growth (3Y)(%) -17.50
LXRX's EBITDA Growth (3Y)(%) is ranked lower than
66% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. LXRX: -17.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
LXRX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -28.4  Med: -14.60 Max: 22.6
Current: -17.5
-28.4
22.6
EPS Growth (3Y)(%) -18.20
LXRX's EPS Growth (3Y)(%) is ranked lower than
66% of the 418 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. LXRX: -18.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
LXRX' s 10-Year EPS Growth (3Y)(%) Range
Min: -26.5  Med: -11.20 Max: 30.8
Current: -18.2
-26.5
30.8
» LXRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

LXRX Guru Trades in Q3 2014

Paul Tudor Jones 29,223 sh (+18.60%)
Mario Gabelli 160,200 sh (unchged)
Chuck Royce 2,736,133 sh (-5.20%)
» More
Q4 2014

LXRX Guru Trades in Q4 2014

Jim Simons 695,910 sh (New)
Paul Tudor Jones 53,297 sh (+82.38%)
Chuck Royce 2,813,833 sh (+2.84%)
Mario Gabelli 105,200 sh (-34.33%)
» More
Q1 2015

LXRX Guru Trades in Q1 2015

Joel Greenblatt 73,566 sh (New)
Jim Simons 1,636,131 sh (+135.11%)
Mario Gabelli 105,200 sh (unchged)
Chuck Royce 2,813,833 sh (unchged)
Paul Tudor Jones 29,223 sh (-45.17%)
» More
Q2 2015

LXRX Guru Trades in Q2 2015

Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
Mario Gabelli 14,285 sh (-86.42%)
Chuck Royce 377,074 sh (-86.60%)
Jim Simons 170,153 sh (-89.60%)
» More
» Details

Insider Trades

Latest Guru Trades with LXRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.69
LXRX's P/B is ranked lower than
61% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. LXRX: 5.69 )
Ranked among companies with meaningful P/B only.
LXRX' s 10-Year P/B Range
Min: 0.66  Med: 3.04 Max: 10.17
Current: 5.69
0.66
10.17
P/S 45.32
LXRX's P/S is ranked lower than
79% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.47 vs. LXRX: 45.32 )
Ranked among companies with meaningful P/S only.
LXRX' s 10-Year P/S Range
Min: 2.63  Med: 23.62 Max: 2016
Current: 45.32
2.63
2016
Current Ratio 7.20
LXRX's Current Ratio is ranked higher than
65% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. LXRX: 7.20 )
Ranked among companies with meaningful Current Ratio only.
LXRX' s 10-Year Current Ratio Range
Min: 0.95  Med: 6.86 Max: 31.11
Current: 7.2
0.95
31.11
Quick Ratio 7.20
LXRX's Quick Ratio is ranked higher than
66% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. LXRX: 7.20 )
Ranked among companies with meaningful Quick Ratio only.
LXRX' s 10-Year Quick Ratio Range
Min: 0.95  Med: 6.86 Max: 31.11
Current: 7.2
0.95
31.11
Days Sales Outstanding 4.79
LXRX's Days Sales Outstanding is ranked higher than
94% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. LXRX: 4.79 )
Ranked among companies with meaningful Days Sales Outstanding only.
LXRX' s 10-Year Days Sales Outstanding Range
Min: 5.95  Med: 53.79 Max: 461.86
Current: 4.79
5.95
461.86

Valuation & Return

vs
industry
vs
history
Price/Net Cash 13.35
LXRX's Price/Net Cash is ranked lower than
69% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. LXRX: 13.35 )
Ranked among companies with meaningful Price/Net Cash only.
LXRX' s 10-Year Price/Net Cash Range
Min: 1.17  Med: 5.98 Max: 92.26
Current: 13.35
1.17
92.26
Price/Net Current Asset Value 10.15
LXRX's Price/Net Current Asset Value is ranked lower than
62% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 6.84 vs. LXRX: 10.15 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
LXRX' s 10-Year Price/Net Current Asset Value Range
Min: 1.13  Med: 5.13 Max: 302.75
Current: 10.15
1.13
302.75
Price/Tangible Book 9.84
LXRX's Price/Tangible Book is ranked lower than
72% of the 690 Companies
in the Global Biotechnology industry.

( Industry Median: 5.33 vs. LXRX: 9.84 )
Ranked among companies with meaningful Price/Tangible Book only.
LXRX' s 10-Year Price/Tangible Book Range
Min: 0.89  Med: 3.92 Max: 45.08
Current: 9.84
0.89
45.08
Price/Median PS Value 1.92
LXRX's Price/Median PS Value is ranked lower than
76% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: 1.07 vs. LXRX: 1.92 )
Ranked among companies with meaningful Price/Median PS Value only.
LXRX' s 10-Year Price/Median PS Value Range
Min: 0.11  Med: 0.59 Max: 64.46
Current: 1.92
0.11
64.46
Earnings Yield (Greenblatt) (%) -8.30
LXRX's Earnings Yield (Greenblatt) (%) is ranked lower than
57% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. LXRX: -8.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
LXRX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -18.5  Med: 157.90 Max: 11682.1
Current: -8.3
-18.5
11682.1

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 21 2 32
EPS($) -0.92 -1.36 -1.14
EPS without NRI($) -0.92 -1.36 -1.14

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:LX31.Germany,
Lexicon Pharmaceuticals Inc was incorporated in Delaware on July 7, 1995. The Company operates as a biopharmaceutical company engaged in discovery and development of breakthrough treatments for human disease. It has used its proprietary gene knockout technology and an integrated platform of advanced medical technologies to systematically study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as potential drug targets. It has identified and validated in living animals, or in vivo, more than 100 targets with promising profiles for drug discovery. The Company has also advanced small molecule compounds from a number of additional drug programs into various stages of preclinical development and research and believe that its systematic, target biology-driven approach to drug discovery will enable it to continue to expand its clinical pipeline. It faces significant competition in each of the aspects of its business from other pharmaceutical and biotechnology companies. The development, manufacture and sale of any drug or biologic products developed by the Company or its collaborators will be subject to extensive regulation by United States and foreign governmental authorities, including federal, state and local authorities.
» More Articles for LXRX

Headlines

Articles On GuruFocus.com
Lexicon Genetics Inc. Reports Operating Results (10-Q) Nov 08 2010 
Lexicon Genetics Inc. Reports Operating Results (10-Q) Aug 09 2010 
Lexicon Genetics Inc. Reports Operating Results (10-Q) May 10 2010 
Lexicon Genetics Inc. Reports Operating Results (10-Q) Oct 30 2009 
Lexicon Genetics Inc. Reports Operating Results (10-Q) Aug 06 2009 
Lexicon Genetics Inc. Reports Operating Results (10-Q) Apr 30 2009 

More From Other Websites
Lexicon to Report Second Quarter 2015 Financial Results on August 7, 2015 Aug 26 2015
Lexicon Announces Telotristat Etiprate Data to be Presented at European Cancer Congress Aug 26 2015
Lexicon Announces Telotristat Etiprate Data To Be Presented At European Cancer Congress Aug 26 2015
LEXICON PHARMACEUTICALS, INC. Financials Aug 20 2015
Lexicon To Present At The 2015 Wedbush PacGrow Healthcare Conference Aug 10 2015
Lexicon Pharma downgraded by JP Morgan Aug 10 2015
Edited Transcript of LXRX earnings conference call or presentation 7-Aug-15 12:30pm GMT Aug 08 2015
Lexicon Pharmaceuticals Reports 2nd Quarter Financial Results, Provides Clinical Pipeline Update Aug 07 2015
Lexicon reports 2Q loss Aug 07 2015
Lexicon reports 2Q loss Aug 07 2015
LEXICON PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 07 2015
Q2 2015 Lexicon Pharmaceuticals Inc Earnings Release - Before Market Open Aug 07 2015
Lexicon Pharmaceuticals Reports 2nd Quarter Financial Results, Provides Clinical Pipeline Update Aug 07 2015
Lexicon to Report Second Quarter 2015 Financial Results on August 7, 2015 Aug 05 2015
Biotech Stock Roundup: Baxalta Rejects Shire Bid, Amgen's Beat & Raise Quarter - Analyst Blog Aug 05 2015
Lexicon Shares Soar After Success in Late-Stage Cancer Drug Trial Aug 04 2015
Lexicon CEO: Carcinoid Drug Offers Biggest Advance in Over a Decade Aug 04 2015
Woodlands-based pharma company CEO: We're a '20-year-old overnight sensation' Aug 04 2015
Mid-Morning Market Update: Markets Edge Higher; Coach Beats Q4 Expectations Aug 04 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK